Cystic fibrosis (CF) is the most common autosomal-recessive genetic disorder in man. The disease affects not only the lungs, but also the pancreas, liver, kidneys, and intestine. Long-term clinical issues include difficulty breathing and coughing up thick mucus, which promotes frequent lung infections. Other signs and symptoms may include sinus infections, poor growth, fatty stools, clubbing of the fingers and toes, and infertility in male patients. Earlier, patients died in childhood, although modern treatments have completely altered that state-of-affairs. Depending upon the mutations, the patients may have varying degrees of symptoms [1] .
A mutation in the gene, cystic fibrosis transmembrane conductance regulator (CFTR) causes CF. Over 1500 CFTR mutations have been described, although the most common mutation, ΔF508, is a deletion of three nucleotides that results in a loss of the amino acid phenylalanine at the 508th position on the protein. This mutation accounts for two thirds (66-70%) of CF cases worldwide [2] . The CFTR protein is anchored to the outer membrane of cells in the sweat glands, lungs, pancreas, and all other exocrine glands in the body. CFTR acts as a channel and is responsible for controlling the movement of chloride from inside to outside of cells. The damage in CF is caused by blockage of narrow passageways in affected organs with thickened secretions.
The lungs of CF patients are colonized and infected by bacteria from an early age. These bacteria thrive in the altered mucus, which collects in the small airways of the lungs. This mucus leads to the formation of bacterial microenvironments, termed biofilms, which are difficult for immune cells and antibiotics to penetrate. Viscous secretions and persistent respiratory infections, commonly Pseudomonas aeruginosa, repeatedly damage the lung by gradually remodeling the airways, which makes infection even more difficult to eradicate (Fig. 1) [3] .
Sphingomyelin is a type of sphingolipid found in animal cell membranes, especially in the membranous myelin sheath that surrounds nerve cell axons. Sphingomyelin consists of a phosphocholine head group, a sphingosine, and a fatty acid. Sphingomyelin is enriched at the plasma membrane with a greater concentration on the outer than the inner leaflet. The sphingomyelinase pathway uses an enzyme to break down sphingomyelin in the cell membrane and release ceramide. Ceramides are a family of waxy lipid molecules, composed of sphingosine and a fatty acid. Contrary to previous assumptions that ceramides and other sphingolipids found in cell membrane were purely supporting structural elements, ceramide can participate in a variety of cellular signaling events. Examples include regulating differentiation, proliferation, and programmed cell death [4] . Lipid rafts are plasma membrane microdomains that are highly enriched in cholesterol and sphingolipids. Stimulation of CD95 or CD40 receptors activates sphingomyelinase in lipid rafts. As a result, ceramides are produced through the degradation of sphingomyelins. Sphingolipids have been strongly implicated in lung growth, maintenance, and repair [5] .
Ceramide accumulation has been implicated in the pathogenesis of CF. Ceramide accumulates in the lungs of CF patients, causing inflammation and an increased susceptibility to bacterial infections. The possibility has been raised that interfering with sphingolipids could be of therapeutic relevance in CF patients [6] . Indeed, fenretinide (4-hydroxy phenylretinamide) is a synthetic retinoid derivative, related to vitamin A. Fenretinide has been investigated for potential use in the treatment of cancer, rheumatoid arthritis, acne, psoriasis, and CF [7] . In an earlier study, Mcilroy et al. showed that fenretinide-mediated retinoic acid receptor signaling and inhibition of ceramide biosynthesis regulates adipogenesis, lipid accumulation, mitochondrial function, and nutrient stress signaling in adipocytes and adipose tissue. Their findings suggested that fenretinide utilizes retinoid-acid-receptor (RAR)-dependent and independent pathways to regulate cell biology that could be relevant to the current results [8] .
The authors of this month's J Mol Med Garić et al. show a restoration of CFTR expression when aberrant levels of specific ceramides, as determined by means of a mass spectrometry assay, are reduced to normal [9] . Furthermore, they demonstrate a correlation between CFTR protein expression and regulation of specific ceramide levels. They first demonstrated that very-long-chain ceramide species are reduced, while long-chain ceramide expression (14-18 carbons) is increased in Cftr knockout mice, compared to controls [9] . Petrache et al. had suggested earlier that increased long-chain ceramides lead to increased inflammation in the lungs [10] . Garić et al. then treated Cftr knockout mice with fenretinide for 4 weeks [9] . The treatment brought about downregulation of long-chain ceramides, while actually increasing very-longchain ceramides. The authors also treated CF patients with fenretinide. The treatment had heterogeneous effects so that the 15 patients were divided into responders or nonresponders. Nevertheless, 300 mg daily of fenretinide in these patients appeared to normalize the balance between long-chain and very-long-chain ceramides. Non-CF persons showed no effects of these treatments, nor did placebo treatment exert any effect.
The authors also found that pulmonary epithelial cells homozygous for CFTR ΔF508 also exhibited a favorable ceramide expression response after exposure to fenretinide [9] . In these experiments, authors used a lentiviral vector encoding functional CFTR protein. The investigators again found reduced long-chain ceramide expression and increased verylong-chain ceramide expression. Interestingly, treatment with zinc also influenced the results in a similar fashion. The authors suggest that transcriptional regulation could be responsible for their results.
Seitz et al. [11] indicate that ceramide accumulates in the airway epithelium of CF and ceramide synthase 2 (CerS2)-deficient mice, which respond to the lack of very-long-chain (C22-C24-) ceramides with a profound compensatory increase of long-chain (mainly C16-) ceramides. In contrast, sphingosine is present in healthy airways and is almost completely absent from diseased or deficient epithelial cells. Both sphingolipids are crucially involved in the high susceptibility to infection of CF and CerS2-deficient mice, as indicated by findings showing that the normalization of ceramide and sphingosine levels rescue these mice from acute infection with P. aeruginosa. Both sphingolipids could be crucially involved in the high susceptibility to infection in CF and CerS2-deficient mice, as indicated by findings showing that the normalization of ceramide and sphingosine levels rescue these mice from acute infection with P. aeruginosa. How could fenretinide work? Fenretinide is a peroxisome proliferator-activated receptor-γ (PPARγ) ligand. Interestingly, PPARγ has been implicated as a therapeutic target in CF and its function has been known to be severely reduced in CF [12] . The PPARγ agonist, rosiglitazone was withdrawn from the market. However, pioglitazone remains available in some countries. Interestingly, PPARγ agonists were recently shown to reduce biofilm formation by P. aeruginosa [13] . Intriguing information for CF patients, whose outlook appears to be improving.
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